Coverage of IDWeek 2017
- Details
- Category: HIV Treatment
- Published on Thursday, 30 November 2017 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of IDWeek 2017, held October 4-8, 2017, in San Diego.
- Long-Acting Monoclonal Antibody Effective Against Multidrug-Resistant HIV
- Single-Tablet Protease Inhibitor Regimen Maintains Viral Suppression for a Year
11/30/17
Coverage of IDWeek 2016
- Details
- Category: HIV Treatment
- Published on Friday, 04 November 2016 00:00
- Written by HIVandHepatitis.com
HIVandHepatitis.com coverage of IDWeek 2016, held October 26-30 in New Orleans.
Conference highlights include experimental HIV therapies, PrEP and other biomedical HIV prevention, antibiotic resistance, and emerging infectious diseases such as Ebola virus and Zika virus.
Full listing of coverage by topic
11/4/16
IDWeek 2015: Post-Treatment Control of HIV Appears Rare, Biomarkers May Help Predict Rebound
- Details
- Category: Search for a Cure
- Published on Tuesday, 20 October 2015 00:00
- Written by Liz Highleyman
Only 4 individuals out of nearly 5000 people receiving care at U.S. military health facilities were found to exhibit immune control of HIV after starting antiretroviral therapy (ART), achieving viral suppression, and interrupting treatment, according to a presentation at IDWeek 2015 this month in San Diego. A recently published related study identified several biomarkers that may help predict who will be post-treatment controllers, a useful tool for HIV cure research.
IDWeek 2015: HIV/HCV Coinfected People Achieve High Cure Rates with Grazoprevir/Elbasvir
- Details
- Category: HCV Treatment
- Published on Wednesday, 11 November 2015 00:00
- Written by Liz Highleyman
A dual combination of Merck's grazoprevir and elbasvir taken for 12 or 16 weeks cured most HIV-positive people coinfected with hepatitis C virus (HCV) genotypes 1, 4, or 6, and was generally safe and well-tolerated, according to an integrated analysis of three trials presented at the recent IDWeek 2015 conference in San Diego.
IDWeek 2015: Sofosbuvir + Daclatasvir Demonstrates High Cure Rates for HIV/HCV Coinfected People
- Details
- Category: HIV/HCV Coinfection
- Published on Monday, 19 October 2015 00:00
- Written by Liz Highleyman
Nearly all people with HIV and genotype 1-4 HCV coinfection treated for 12 weeks with an interferon-free regimen of sofosbuvir (Sovaldi) plus daclatasvir (Daklinza) achieved sustained virological response in the ALLY-2 trial, but 8 weeks did not work as well, according to a report in the August 20 New England Journal of Medicine. Substudies presented this month at IDWeek 2015 showed that this regimen is highly effective regardless of race or specific antiretroviral regimen.
More Articles...
- IDWeek 2015: Many People with HIV Are Not Virally Suppressed on Antiretroviral Therapy
- IDWeek 2015: Emergency Needle Exchange Reduces HIV and HCV Risk in Indiana
- IDWeek 2015: Studies Continue to Support Tenofovir Alafenamide as it Nears Approval
- IDWeek 2015: HIV Attachment Inhibitor BMS-663068 Matches Atazanavir in Phase 2b Study
- IDWeek 2015: Hepatitis C Mortality Continues to Increase in the U.S.
- IDWeek 2015: Affordable Care Act Coverage Improves Chances of HIV Viral Suppression
- IDWeek 2015 Features HIV and Hepatitis C Prevention, Treatment, and Cure Research
- Coverage of IDWeek 2015
Web Design and Development by